209 citations
,
March 1989 in “Journal of The American Academy of Dermatology” This study found that recombinant human leukocyte interferon alfa-2a achieved a 64% overall antitumor response rate in patients with early and advanced cutaneous T cell lymphoma and was generally well-tolerated.
107 citations
,
December 2003 in “Dermatologic Therapy” This paper reviews the use of interferons, particularly alfa interferon, in treating cutaneous T-cell lymphoma, noting its substantial efficacy both alone and in combination therapies with predictable, generally well-tolerated side effects.
39 citations
,
May 2004 in “Clinics in Dermatology” This article reviews treatment options for cutaneous T-cell lymphoma, including skin-directed therapies and aggressive treatments for advanced cases, but reports no new clinical results.
35 citations
,
October 2021 in “Journal of the European Academy of Dermatology and Venereology” This report describes two cases where a viral vector COVID-19 vaccine was associated with the recurrence of cutaneous lymphoma conditions that had been in remission.
28 citations
,
September 2014 in “Journal of Veterinary Internal Medicine” This study found that the novel drug VDC-1101 showed a 45% objective response rate in treating canine cutaneous T-cell lymphoma, offering a potential treatment option for this challenging disease.